731results about "Tetrapeptide ingredients" patented technology

The invention discloses an oligopeptide from undaria pinnatifida and application thereof. The amino acid sequence of the oligopeptide is YRKD, and the molecular weight is 580.63 g / mol. The polypeptide is identified from undaria pinnatifida through a high performance liquid chromatography technology for the first time, and an unreported oligopeptide capable of inhibiting tyrosinase and cooperating with vitamin C to synergistically inhibit tyrosinase is screened out. The oligopeptide derived from undaria pinnatifida is synthesized by a solid phase method, has the characteristics of safety, no toxicity, good water solubility and good stability, and is combined with vitamin C to generate a synergistic effect and synergistically increase the inhibition effect on tyrosinase, so that the oligopeptide can achieve a better tyrosinase inhibition effect at a lower and more stable concentration; the use concentration of the oligopeptide can be greatly reduced, the stability is enhanced, and the oligopeptide can be widely applied to preparation of cosmetics, medicines, health-care products or food additives, and has important economic value and social significance.

Compositions and methods for treating diseases associated with dysregulation of miR-21, particularly cancer, are disclosed.

The invention discloses a blood protein precise active peptide capable of tonifying qi and blood, improving microcirculation and promoting vasodilation and a preparation method and application thereof, and belongs to the technical field of blood protein peptide. The blood protein precision active peptide comprises at least one of LGFP, IGFP, FPHFN, LFL, LFI, FESF, ILF, LIF, FLL, FIL, FII or FPHFD. The prepared blood protein precision active peptide has multiple biological activities: an antihypertensive effect is achieved by inhibiting ACE and vasoconstriction substances; vasodilation is promoted by activating a PI3K / AKT / eNOS signal channel; a zebra fish model proves that the traditional Chinese medicine composition has the effects of remarkably improving microcirculation and tonifying qi and blood. The preparation method is low in equipment requirement, simple in process, easy to operate and convenient for industrial large-scale production. The method enriches a bioactive peptide library, and is of great significance in promoting technical progress and industrial upgrading in the field of hemoglobulin peptides.

Isolated or recombinant EphA5 or GRP78 targeting antibodies are provided. In some cases, antibodies of the embodiments can be used for the detection, diagnosis and / or therapeutic treatment of human diseases, such as cancer. A method of rapidly identifying antibodies or antibody fragments for the treatment of cancer using a combination of in vitro and in vivo methodologies is also provided.

The invention provides a TF and Her2 targeting bispecific antibody coupling drug as well as a preparation method and application thereof, and belongs to the technical field of biological drug preparation. The bispecific antibody provided by the invention can target TF and / or Her2 antigens in tumor cells, and has the advantages of high stability, easiness in expression, purification and coupling and the like. The bispecific antibody can be specifically combined with a tumor surface antigen and internalized into tumor cells, so that the tumor cells can be specifically killed. The bispecific antibody coupling drug prepared on the basis of the bispecific antibody has a good tumor inhibition effect in a cell model and an animal model, is nontoxic and harmless to animals, and has an excellent cancer treatment potential.

The invention provides a milk protein peptide which takes milk protein as a raw material and has the effects of promoting calcium absorption and improving bone health and application of the milk protein peptide. Specifically, milk protein peptide sequences, including YGGVSL and SQRY, are screened by adopting enzymolysis, sequence identification and molecular docking methods. The milk protein peptide is proved to have high calcium transport promoting capacity in the in-vitro intervention of Caco-2 cells, and the milk protein peptide is proved to have the capacity of promoting osteogenesis and inhibiting bone resorption in the in-vitro intervention of MC3T3-E1 mouse embryo osteoblasts. In animal experiments, by increasing the content of blood calcium and bone calcium, reducing the content of excrement calcium, improving mRNA expression of calcium ion channel protein, calcium binding protein and peptide transporter in intestinal tracts, enhancing the efficiency of calcium entering blood, promoting osteogenesis and inhibiting bone resorption, the milk protein peptide is comprehensively proved to have the capabilities of improving calcium resorption of organisms and improving bone health. The milk protein peptide has both functionality and nutrition, and has a wide application prospect in the aspect of bone health.

The invention relates to an application of a CAR exosome drug carrier in tumor treatment. The application of the CAR exosome loaded medicine in tumor treatment is based on the strategy of CAR exosome coupling medicine, so that the completeness of the exosome and the controllability of the medicine loading capacity are greatly protected, the purpose of accurately delivering the medicine to tumors in a targeted manner is achieved, and a new direction is provided for tumor treatment.

The tumor stroma, which accounts for a large portion of the tumor mass, is an attractive target for the delivery of diagnostic and therapeutic compounds. Here, we focus specifically on a subpopulation of stromal cells known as cancer-associated fibroblasts, which are present in over 90% of epithelial cancers, including pancreatic, colon, and breast cancers. Cancer-associated fibroblasts are characterized by high expression of FAPs, which are undetectable in adult normal tissues but are associated with poor prognosis in cancer patients. The present invention provides small molecule radiopharmaceuticals and imaging agents based on FAP-specific inhibitors.

Disclosed are a peptide amide compound composition, a preparation method therefor and medical use thereof. Specifically, the composition contains a compound of formula (I) and pH regulators, and the pH of the solution thereof is 3-5.5. The composition is stable and requires few excipients, and is stable in clinical use. The composition is used for treating or preventing a disease or condition associated with kappa opioid receptors

The invention discloses a preparation method of a fructus cannabis protein peptide product with effects of resisting fatigue and improving exercise ability, which comprises the following steps: performing preliminary crushing, ultralow-temperature freezing micro-crushing and low-temperature continuous phase-change extraction degreasing on fructus cannabis, performing step-by-step hydrolysis by using polysaccharase and 2.4 L bacterial protease to extract fructus cannabis protein, performing low-temperature salting-out, and performing freeze-drying to obtain the fructus cannabis protein peptide product with the effects of resisting fatigue and improving exercise ability. The fructus cannabis protein peptide powder is prepared through low-temperature ultrasonic dissolution promotion, high-pressure micro-jet homogenization, compound enzyme C hydrolysis, 1% pepsase, high-temperature enzyme deactivation, chlorophyll removal through counter-current extraction, hydrogen peroxide decoloration, ultralow-temperature instantaneous concentration, low-temperature vacuum belt type drying and low-temperature ultrahigh-pressure sterilization. The fructus cannabis protein peptide prepared by the invention has the following remarkable effects: 1, the exercise ability is remarkably improved, the accumulation of lactic acid and urea nitrogen is reduced, the exhaustion time is prolonged, and the physical and mental fatigue is relieved; 2, the content of hepatic glycogen and muscle glycogen is obviously increased, the energy reserve of the body is increased, the explosive power and the reactivity are improved, and the athletic performance is improved; and 3, the antioxidant level of the body is improved, and fatigue and immune recovery after exercise are promoted.

Use of an active peptide in the manufacture of a product to improve the skin barrier and promote collagen expression and / or increase skin elasticity and suppleness and / or reduce wrinkles, characterized in that the active peptide has the structural formula HA-OH, wherein A comprises at least two amino acid residues, and the amino acid residues comprise at least one from Hyp, Gly, Pro and Ala.

The invention discloses liver peptide capable of protecting liver and improving asthenopia as well as a preparation method and application of the liver peptide, and belongs to the technical field of biology. The liver peptide contains at least one of DAIP, SPF, DIAP, SLP, AVGP or NLP, and the prepared liver peptide has multiple physiological effects: the liver peptide can effectively activate ADH enzyme activity, reduce ALT and AST levels and protect liver cells; the lipid metabolism is improved by regulating and controlling the expression of the SREBP-1c, the FAS and the PPAR-alpha genes; meanwhile, the antioxidant capacity is remarkable, the ROS level can be reduced, and the SOD content and the CAT content can be increased; the expression of RPE65 and LRAT genes can be up-regulated, and the visual function is maintained. The method disclosed by the invention is simple in process and convenient to operate, the obtained liver peptide can be widely applied to the field of functional products for protecting the liver, improving visual fatigue and the like, and an innovative solution is provided for high-value utilization of liver resources.

The invention relates to the field of polypeptides, in particular to a black ginseng polypeptide and a preparation method and application thereof. The black ginseng polypeptide is obtained by taking black ginseng as a raw material through high-pressure homogenization wall breaking and alkaline protease enzymolysis. The polypeptide has an anti-aging function. The black ginseng polypeptide provided by the invention is more efficient, safer and more environment-friendly, and has a good application prospect in the fields of cosmetics, functional foods and biological medicines.

Compositions comprising specific tetrapeptides, for use in methods for treating, preventing, minimizing, diminishing or reversing various signs of aging of the skin are provided. The compositions are useful in improving the firmness or elasticity of skin, smoothing of fine-lines or wrinkles, reducing skin pores and hyperpigmentation, and increasing skin thickness, radiance and / or softness.

Provided is a more useful antitumor drug that is the result of further advancing conventional antibody-drug conjugates. An antibody-multidrug conjugate represented by general formula (I): [in the formula, the symbols have the meanings set forth in the description of the present application] or a pharmacologically acceptable salt thereof.

The present disclosure relates to eribulin derivative drug conjugates, their preparation methods, and their pharmaceutical applications. Specifically, the present disclosure provides antibody-drug conjugates containing an eribulin derivative drug moiety. The present disclosure also relates to methods for treating cancer by administering the antibody-drug conjugates provided herein.

This invention belongs to the fields of biomedicine, beauty, and personal care health technology, and discloses a dual-target oil-controlling peptide co-amorphous assembly, its preparation method, and its application. The method involves adding capryloylglycine and acetyl tetrapeptide-5 to an alcohol solution, heating to dissolve, rotary evaporating, and drying to obtain a co-amorphous compound. This compound is then mixed with a cyclodextrin compound and water, rotary evaporating, and drying to obtain the dual-target oil-controlling peptide co-amorphous assembly. This invention employs a co-amorphous combination with cyclodextrin inclusion to assemble acetyl tetrapeptide-5 and capryloylglycine, solving the problem of their large solubility differences and difficulty in coexistence, and significantly improving the solubility of capryloylglycine. This assembly enables simultaneous transdermal delivery of the two active components through nano-assembly, helping to enhance the stability of acetyl tetrapeptide-5 and reduce its oxidative degradation. The two components synergistically control oil through a dual pathway of inhibiting 5α-reductase and targeting the MC5R receptor, respectively, exhibiting superior bioavailability and efficacy compared to a single component.

The present invention relates to antibody-drug conjugates (ADCs) that target the receptor uPARAP, and in particular to antibody-drug conjugates (ADCs) comprising humanized antibodies directed against uPARAP, and their use in delivering active agents to cells and tissues expressing exatecan derivatives and uPARAP. The present invention further relates to the use of the ADCs in the treatment of diseases involving uPARAP-expressing cells, such as certain cancers.

The present disclosure relates to anti-PTK7 antibodies or antigen-binding fragments thereof, nucleic acid molecules encoding the same, and use thereof in preparation of antibody-drug conjugates, and further relates to antibody-drug conjugates containing the antibodies or antigen-binding fragments thereof and preparation method and use thereof.

Cosmetic method for improving skin characteristics, in which the cleansed skin surface is sprayed with water containing four-atom oxygen, known in itself as activated stabilized oxygen, and then, after the skin has absorbed the spray, the surface is coated with a preparation containing at least 0.040% by weight of hydrolyzed beta-glucan, preferably 0.1% by weight, wherein the preparation also contains at least 0.04% by weight, preferably 0.1 w% acetyl tetrapeptide-40, in the form of a gel or cream, and then the pretreated skin surface is irradiated with soft laser light emitting scattered rays with a wavelength of 700-900 nm and a power density of 40-200 mW cm2 power density, where the irradiation time is at least 30 seconds, depending on the power density. The composition contains at least 0.040% by weight of hydrolyzed beta-glucan, 1-5% by weight of a moisturizing agent, 15-20% by weight of a skin conditioning agent, 1-5% by weight of a preservative, and at least 0.04% by weight of acetyl tetrapeptide-40.

The application provides a bispecific antibody conjugate drug targeting TF and Her2, and a preparation method and application thereof, and belongs to the technical field of biological drug preparation. The bispecific antibody provided by the application can target TF and / or Her2 antigens in tumor cells, has high stability, and has the advantages of easy expression, purification and conjugation. The bispecific antibody can specifically bind to tumor surface antigens and be internalized into tumor cells, and can specifically kill tumor cells. The bispecific antibody conjugate drug prepared based on the bispecific antibody has good tumor inhibition effect in a cell model and an animal model, is non-toxic and harmless to animals, and has excellent potential for treating cancer.

The application discloses a small-molecule peptide from fermented mare milk, which has an amino acid sequence of His-Ala-Trp-Phe and a molecular weight of 559.67 Da. The small-molecule peptide has pancreatic lipase inhibitory activity, can be applied to the preparation of a medicine for reducing high blood fat, and is simple to prepare, suitable for industrialized production and market promotion and application.

The present application relates to the technical field of biological medicine, and particularly relates to a polypeptide with broad-spectrum antiviral activity and application. The amino acid sequence of the polypeptide comprises at least one of SEQ ID NO: 1-10 or a derivative obtained from the same. The polypeptide acting on LV uses a concentration of 20 μM; the polypeptide acting on H1N1 uses a concentration of 50 μM. The innovative mechanism is to directly act on the virus particles, interfere with the packaging and assembly process, and cause the virus to form non-infective defective particles. In vitro experiments prove that polypeptides such as KV7 and DK8 can dose-dependently destroy the virus morphology, and the inhibition rate of polypeptides such as KD5, VV14 and KV14 on H1N1 is more than 95%. Animal experiments prove that after the polypeptide KD5 is premixed with the virus, the polypeptide is administered by inhalation, and the virus replication in the lung tissue of the infected mice can be significantly inhibited. The present application has the outstanding advantages of broad-spectrum high efficiency, novel mechanism, and suitability for inhalation administration.

An object of the present invention is to provide a prophylactic and / or therapeutic agent for amyotrophic lateral sclerosis. A prophylactic and / or therapeutic agent for amyotrophic lateral sclerosis, comprising at least one compound selected from the group consisting of paclitaxel, docetaxel, carfilzomib, olaparib, and nicotinamide.

This invention discloses an anti-inflammatory peptide derived from pearl oysters and its applications, relating to the field of bioactive peptide technology. The amino acid sequence of this anti-inflammatory peptide is TAMY. The anti-inflammatory peptide derived from pearl oysters provided by this invention can regulate the release of cellular inflammatory mediators, reduce the levels of NO and pro-inflammatory cytokines (such as TNF-α, IL-6, and IL-1β), and simultaneously promote the secretion of anti-inflammatory cytokines (such as IL-10), exhibiting excellent anti-inflammatory activity and suitable for use in functional foods, cosmetics, or pharmaceutical ingredients.

The invention relates to a novel polypeptide and application thereof. The polypeptide provided by the invention is short in peptide chain and faster and better in absorption. Experimental results show that the polypeptide provided by the invention shows an obvious enteric cavity dilatation relieving effect in pharmacodynamic tests of a zebra fish inflammatory bowel disease model and a rat inflammatory bowel disease model. The polypeptide provided by the invention has a remarkable colitis relieving effect, and can be used for preparing a medicine for treating enteritis, especially a medicine for treating ulcerative colitis.

Bioactive walnut peptides and use of the bioactive walnut peptides for topical application to the scalp are described. The bioactive walnut peptides may be incorporated into a pharmaceutical or cosmetic composition for application to the scalp. The pharmaceutical or cosmetic compositions and the one or more bioactive walnut peptides in the compositions are particularly useful for treating or preventing hair loss, and treating scalp conditions, such as dandruff, scalp psoriasis, and acne.

The disclosure provides methods for the acute treatment of depression and / or anxiety, for the enhancement of mTOR (e.g., mTORC1) signaling, and for the reduction of neuroinflammation, comprising administering to a patient in need thereof, a therapeutically effective amount of a 5-HT2A or 5-HT2A / D2 receptor ligand, e.g. lumateperone.

The present disclosure provides linker-payload conjugates including a bioorthogonal group and a hydrophilic moiety. The improved linker-payloads for antibody conjugation and improved antibody drug conjugates (ADCs) exhibit greater stability in blood circulation and enhanced drug delivery and drug release efficiencies in target cells. The present disclosure also relates to antibodies and antigen-binding fragments thereof for several antigen targets (e.g. TROP2, HER2, Nectin-4, etc.), as well as pharmaceutical compositions including ADCs. Also described herein are methods of using ADCs for treatment of subjects associated with pathological conditions.

The invention discloses a novel active peptide composition for improving concentration and a preparation method and application thereof. Belongs to the technical field of new active peptide composition preparation. The novel active peptide composition is prepared through synergism of the novel active peptide PAVP, the blood-brain barrier penetrating peptide and the metabolism regulator, when the novel active peptide PAVP, the blood-brain barrier penetrating peptide and the metabolism regulator act together, the novel active peptide composition has a synergistic effect, and the concentration improving effect of the novel active peptide composition is better than that of each independent component; the time for the mouse to explore new things can be prolonged to a certain extent, the relative expression quantity of synaptic plasticity markers PSD-95, BDNF and p-CREB can be increased to a certain extent, and technical support is provided for research and development of concentration-related products.